PFE · 8-K · 20260804PR000094
Oncology Portfolio Growth
PFIZER INC · 2026-08-04 · Importance 69 · Surprise 64
Worldwide Oncology revenue increased 3% to $4.165 billion in the second quarter and 6% to $7.991 billion for the first six months. Growth was led by Padcev, up 23% worldwide to $667 million in the quarter, Lorbrena, up 41% to $354 million, and Braftovi/Mektovi, up 23% to $223 million. Orgovyx revenue rose 51% to $146 million, while first-half Padcev revenue increased 30% to $1.258 billion and Lorbrena increased 39% to $659 million. Declines in Adcetris, Bosulif, Tivdak and Inlyta partially offset the growth products.